Contact
searchSearch
HMP Global
Login

Gynecologic Cancer Specialty Channel

Gynecologic Cancer
Specialty Channel
News
Second-Line Bintrafusp Alfa Shows Promise Among Patients With Recurrent or Metastatic Cervical Cancer
08/15/2024
According to a phase 2 study, bintrafusp alfa demonstrated promising clinical activity among patients with recurrent or metastatic cervical cancer.
According to a phase 2 study, bintrafusp alfa demonstrated promising clinical activity among patients with recurrent or metastatic cervical cancer.
According to a phase 2 study,...
08/15/2024
Oncology
News
Tisotumab Vedotin Improved Efficacy Among Patients With Recurrent or Metastatic Cervical Cancer
07/16/2024
According to results from the innovaTV 301 trial, tisotumab vedotin significantly improved efficacy outcomes compared to chemotherapy in the second-or third-line setting among patients with recurrent or metastatic cervical cancer.
According to results from the innovaTV 301 trial, tisotumab vedotin significantly improved efficacy outcomes compared to chemotherapy in the second-or third-line setting among patients with recurrent or metastatic cervical cancer.
According to results from the...
07/16/2024
Oncology
News
Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer
06/18/2024
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the...
06/18/2024
Oncology
FDA Approval
FDA Approves Pembrolizumab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
06/17/2024
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase...
06/17/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
Conference Coverage
Nimotuzumab Plus Concurrent Chemoradiotherapy Improved Response, Survival for Patients With Locally Advanced Cervical Cancer
06/12/2024
According to results from a phase 3 study, the addition of nimotuzumab to concurrent chemoradiotherapy improved response rates and progression-free survival among patients with locally advanced cervical cancer.
According to results from a phase 3 study, the addition of nimotuzumab to concurrent chemoradiotherapy improved response rates and progression-free survival among patients with locally advanced cervical cancer.
According to results from a...
06/12/2024
Oncology
Conference Coverage
Neoadjuvant Sintilimab Plus Chemotherapy Shows Promising Activity Among Patients With Locally Advanced Cervical Cancer
06/03/2024
According to phase 2 data, sintilimab plus paclitaxel and cisplatin in the neoadjuvant setting showed encouraging antitumor activity among patients with locally advanced cervical cancer.
According to phase 2 data, sintilimab plus paclitaxel and cisplatin in the neoadjuvant setting showed encouraging antitumor activity among patients with locally advanced cervical cancer.
According to phase 2 data,...
06/03/2024
Oncology
Conference Coverage
Olaparib Alone As a Chemotherapy-Free Approach Post-Cytoreduction for Patients With Platinum-Sensitive High-Grade Serous Ovarian Cancer
06/03/2024
According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...
According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...
According to phase 2 data to be...
06/03/2024
Oncology
Conference Coverage
Chemoradiotherapy Plus Adjuvant Chemotherapy for High-Risk Cervical Cancer After Radical Hysterectomy
06/03/2024
According to a phase 3 trial, systemic chemotherapy after chemoradiotherapy did not improve disease-free survival or overall survival for patients with cervical cancer with high-risk factors after hysterectomy.
According to a phase 3 trial, systemic chemotherapy after chemoradiotherapy did not improve disease-free survival or overall survival for patients with cervical cancer with high-risk factors after hysterectomy.
According to a phase 3 trial,...
06/03/2024
Oncology
Conference Coverage
Vibostolimab Coformulated With Pembrolizumab Showed Promising Activity Among Patients With dMMR Endometrial Cancer
06/02/2024
The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.
The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.
The phase 2 KEYVIBE-005 study...
06/02/2024
Oncology
FDA Approval
FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
05/01/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase...
05/01/2024
Oncology

News

News
Second-Line Bintrafusp Alfa Shows Promise Among Patients With Recurrent or Metastatic Cervical Cancer
08/15/2024
According to a phase 2 study, bintrafusp alfa demonstrated promising clinical activity among patients with recurrent or metastatic cervical cancer.
According to a phase 2 study, bintrafusp alfa demonstrated promising clinical activity among patients with recurrent or metastatic cervical cancer.
According to a phase 2 study,...
08/15/2024
Oncology
News
Tisotumab Vedotin Improved Efficacy Among Patients With Recurrent or Metastatic Cervical Cancer
07/16/2024
According to results from the innovaTV 301 trial, tisotumab vedotin significantly improved efficacy outcomes compared to chemotherapy in the second-or third-line setting among patients with recurrent or metastatic cervical cancer.
According to results from the innovaTV 301 trial, tisotumab vedotin significantly improved efficacy outcomes compared to chemotherapy in the second-or third-line setting among patients with recurrent or metastatic cervical cancer.
According to results from the...
07/16/2024
Oncology
News
Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer
06/18/2024
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the...
06/18/2024
Oncology
FDA Approval
FDA Approves Pembrolizumab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
06/17/2024
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase...
06/17/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
Conference Coverage
Nimotuzumab Plus Concurrent Chemoradiotherapy Improved Response, Survival for Patients With Locally Advanced Cervical Cancer
06/12/2024
According to results from a phase 3 study, the addition of nimotuzumab to concurrent chemoradiotherapy improved response rates and progression-free survival among patients with locally advanced cervical cancer.
According to results from a phase 3 study, the addition of nimotuzumab to concurrent chemoradiotherapy improved response rates and progression-free survival among patients with locally advanced cervical cancer.
According to results from a...
06/12/2024
Oncology
Conference Coverage
Neoadjuvant Sintilimab Plus Chemotherapy Shows Promising Activity Among Patients With Locally Advanced Cervical Cancer
06/03/2024
According to phase 2 data, sintilimab plus paclitaxel and cisplatin in the neoadjuvant setting showed encouraging antitumor activity among patients with locally advanced cervical cancer.
According to phase 2 data, sintilimab plus paclitaxel and cisplatin in the neoadjuvant setting showed encouraging antitumor activity among patients with locally advanced cervical cancer.
According to phase 2 data,...
06/03/2024
Oncology
Conference Coverage
Olaparib Alone As a Chemotherapy-Free Approach Post-Cytoreduction for Patients With Platinum-Sensitive High-Grade Serous Ovarian Cancer
06/03/2024
According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...
According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...
According to phase 2 data to be...
06/03/2024
Oncology
Conference Coverage
Chemoradiotherapy Plus Adjuvant Chemotherapy for High-Risk Cervical Cancer After Radical Hysterectomy
06/03/2024
According to a phase 3 trial, systemic chemotherapy after chemoradiotherapy did not improve disease-free survival or overall survival for patients with cervical cancer with high-risk factors after hysterectomy.
According to a phase 3 trial, systemic chemotherapy after chemoradiotherapy did not improve disease-free survival or overall survival for patients with cervical cancer with high-risk factors after hysterectomy.
According to a phase 3 trial,...
06/03/2024
Oncology
Conference Coverage
Vibostolimab Coformulated With Pembrolizumab Showed Promising Activity Among Patients With dMMR Endometrial Cancer
06/02/2024
The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.
The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.
The phase 2 KEYVIBE-005 study...
06/02/2024
Oncology

Interactive Features

Quiz
Pembrolizumab Plus Chemotherapy and Bevacizumab vs Placebo in Patients With Cervical Cancer
11/07/2022
Did patients with cervical cancer experience prolonged PFS and OS when treated with pembrolizumab plus chemotherapy and bevacizumab compared to patients treated with placebo?
Did patients with cervical cancer experience prolonged PFS and OS when treated with pembrolizumab plus chemotherapy and bevacizumab compared to patients treated with placebo?
Did patients with cervical...
11/07/2022
Oncology
Test Your Knowledge
Quiz: Is LGSOC Generally Resistant to Chemotherapy?
08/27/2021
True or false: LGSOC comprises 6% to 8% of all ovarian cancers and generally resists chemotherapy with a median survival of approximately 10 years.
True or false: LGSOC comprises 6% to 8% of all ovarian cancers and generally resists chemotherapy with a median survival of approximately 10 years.
True or false: LGSOC comprises...
08/27/2021
Oncology
doc
Test Your Knowledge
Quiz: Upfront MGPT vs Tumor Screening for Lynch Syndrome in Endometrial Cancer
06/02/2021
True or False: Upfront multi-gene panel testing in patients with endometrial cancer has been shown to detect cases of Lynch syndrome not identified by tumor screening.
True or False: Upfront multi-gene panel testing in patients with endometrial cancer has been shown to detect cases of Lynch syndrome not identified by tumor screening.
True or False: Upfront...
06/02/2021
Oncology
Test Your Knowledge
Quiz: A Common Thread in Rising Endometrial Cases in US Women
05/29/2021
Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?
Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?
Quiz: Among young adult women in...
05/29/2021
Oncology
Test Your Knowledge
Quiz: Is Upfront Germline Genetic Testing Encouraged in Endometrial Cancer?
05/28/2021
True or False: Experts opine that upfront germline genetic testing should be considered for patients with any and all solid tumors, including endometrial cancer.
True or False: Experts opine that upfront germline genetic testing should be considered for patients with any and all solid tumors, including endometrial cancer.
True or False: Experts opine...
05/28/2021
Oncology
Test Your Knowledge
Quiz: Is Intensive Follow-Up of Patients Treated for Endometrial Cancer Beneficial?
05/28/2021
True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.
True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.
True or False: Study findings...
05/28/2021
Oncology
Test Your Knowledge
Quiz: Which Therapy Extended PFS for Ovarian Cancer in the ARIEL3 Study?
10/08/2020
According to the ARIEL3 study, _______ extended PFS for ovarian cancer despite toxicities?
According to the ARIEL3 study, _______ extended PFS for ovarian cancer despite toxicities?
According to the ARIEL3 study,...
10/08/2020
Oncology
Test Your Knowledge
Quiz: Does Pembrolizumab Yield Promising Results in Advanced Urothelial Cancer?
09/10/2020
True or False: Pembrolizumab provided a durable clinical response in cisplatin-ineligible patients with advanced urothelial carcinoma and is associated with prolonged OS.
True or False: Pembrolizumab provided a durable clinical response in cisplatin-ineligible patients with advanced urothelial carcinoma and is associated with prolonged OS.
True or False: Pembrolizumab...
09/10/2020
Oncology
Test Your Knowledge
Quiz: Long-Term Maintenance Olaparib for BRCA-Mutated, Relapsed Ovarian Cancer?
06/25/2020
True or false: Maintenance olaparib did not provide a significant OS improvement in a phase 3 study of patients with platinum-sensitive, BRCA-mutated, relapsed ovarian cancer.
True or false: Maintenance olaparib did not provide a significant OS improvement in a phase 3 study of patients with platinum-sensitive, BRCA-mutated, relapsed ovarian cancer.
True or false: Maintenance...
06/25/2020
Oncology
Test Your Knowledge
Quiz: Does Maintenance Pazopanib Improve OS for Advanced Ovarian Cancer?
05/22/2020
True or false: Maintenance pazopanib improved overall survival in advanced ovarian cancer in a phase 3 clinical trial.
True or false: Maintenance pazopanib improved overall survival in advanced ovarian cancer in a phase 3 clinical trial.
True or false: Maintenance...
05/22/2020
Oncology

Recent News

News
Second-Line Bintrafusp Alfa Shows Promise Among Patients With Recurrent or Metastatic Cervical Cancer
08/15/2024
According to a phase 2 study, bintrafusp alfa demonstrated promising clinical activity among patients with recurrent or metastatic cervical cancer.
According to a phase 2 study, bintrafusp alfa demonstrated promising clinical activity among patients with recurrent or metastatic cervical cancer.
According to a phase 2 study,...
08/15/2024
Oncology
News
Tisotumab Vedotin Improved Efficacy Among Patients With Recurrent or Metastatic Cervical Cancer
07/16/2024
According to results from the innovaTV 301 trial, tisotumab vedotin significantly improved efficacy outcomes compared to chemotherapy in the second-or third-line setting among patients with recurrent or metastatic cervical cancer.
According to results from the innovaTV 301 trial, tisotumab vedotin significantly improved efficacy outcomes compared to chemotherapy in the second-or third-line setting among patients with recurrent or metastatic cervical cancer.
According to results from the...
07/16/2024
Oncology
News
Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer
06/18/2024
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the...
06/18/2024
Oncology
FDA Approval
FDA Approves Pembrolizumab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
06/17/2024
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase...
06/17/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
Conference Coverage
Vibostolimab Coformulated With Pembrolizumab Showed Promising Activity Among Patients With dMMR Endometrial Cancer
06/02/2024
The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.
The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.
The phase 2 KEYVIBE-005 study...
06/02/2024
Oncology
FDA Approval
FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
05/01/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase...
05/01/2024
Oncology
News
Gemcitabine Plus Cisplatin and Intensity-Modulated Radiation Therapy Improved Response Rate Among Patients With Unresectable Vulvar Squamous Cell Carcinoma
04/23/2024

Stephanie Holland 

Stephanie Holland 
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...
Results from the phase 2 NRG...
04/23/2024
Oncology
News
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
FDA Approval
FDA Approves Mirvetuximab Soravtansine for Patients With FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
03/25/2024

Stephanie Holland 

Stephanie Holland 
The FDA has approved mirvetuximab soravtansine for previously treated patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, as detected by an FDA-approved test.
The FDA has approved mirvetuximab soravtansine for previously treated patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, as detected by an FDA-approved test.
The FDA has approved...
03/25/2024
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use